NASDAQ:BOLT Bolt Biotherapeutics Q3 2026 Earnings Date & Estimates $3.98 -0.30 (-7.01%) Closing price 03:55 PM EasternExtended Trading$4.03 +0.05 (+1.26%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Bolt Biotherapeutics is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 12, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026Conference Call DateNovember 12, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Bolt Biotherapeutics in Q3 2026Bolt Biotherapeutics is expected to post earnings of -$3.89 per share on revenue of $0.07 million. In the same quarter a year earlier Bolt Biotherapeutics reported -$3.72 per share on revenue of $2.17 million. Bolt Biotherapeutics last reported on August 11, 2026, posting -$4.57 per share and missing the -$3.39 consensus estimate. Bolt Biotherapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$3.89Expected Revenue$0.07 millionPrior-Year EPS-$3.72Prior-Year Revenue$2.17 millionExpected Revenue Growth-96.9%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$4.57 (Missed by -$1.18)Last Quarter Revenue$0.01 millionEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Bolt Biotherapeutics Q3 2026 Earnings FAQ When does Bolt Biotherapeutics report Q3 2026 earnings? Bolt Biotherapeutics (NASDAQ:BOLT) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Bolt Biotherapeutics' Q3 2026 earnings call? Bolt Biotherapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Bolt Biotherapeutics? Analysts expect Bolt Biotherapeutics to post earnings of -$3.89 per share for Q3 2026. How much revenue is Bolt Biotherapeutics expected to report? The consensus revenue estimate for Bolt Biotherapeutics is $0.07 million for Q3 2026. Bolt Biotherapeutics Earnings HeadlinesBolt Biotherapeutics (NASDAQ:BOLT) Stock Price Crosses Below 200-Day Moving Average - Should You Sell?October 7, 2026 | americanbankingnews.comBolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 11, 2026 | globenewswire.comI have publicly predicted six major American crashes, before each one happened.Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 14 at 1:00 AM | Weiss Ratings (Ad)Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | globenewswire.comBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business UpdateMarch 12, 2026 | globenewswire.comBolt Biotherapeutics to Participate in Upcoming March ConferencesFebruary 24, 2026 | globenewswire.comSee More Bolt Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bolt Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bolt Biotherapeutics and other key companies, straight to your email. Email Address About Bolt BiotherapeuticsBolt Biotherapeutics (NASDAQ:BOLT) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is based on its Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, which is designed to combine the tumor-targeting ability of antibodies with agents that activate the innate immune system. Bolt’s approach is intended to recruit and stimulate immune cells within the tumor microenvironment, potentially helping the body recognize and attack cancer cells. The company’s pipeline has included antibody-based immunotherapies directed at tumor-associated targets, including BDC-3042, an investigational Dectin-2 agonist designed to activate myeloid cells and enhance antitumor immune responses. Headquartered in Redwood City, California, Bolt Biotherapeutics was founded to advance new approaches to cancer treatment through immune-system activation. Its programs are being evaluated through clinical development and research activities, with the company’s work focused primarily on oncology applications.View Bolt Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
